HIF Inhibitors: Status of Current Clinical Development

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.

Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · see citing works

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works

Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.

Semenza, G., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,892 · see citing works

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · see citing works

Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1

Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154 · see citing works

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

Du, R., Lu, K. V., Petritsch, C. K., Liu, P., Ganß, R., Passegue, E. A., Song, H., VandenBerg, S. R., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,131 · see citing works

Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.

Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990 · see citing works

Hypoxia-Inducible Factor 1 (HIF-1) Pathway

Semenza, G. L. (2007) · Science s STKE · doi:10.1126/stke.4072007cm8 · Cited by 942 · see citing works

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma

Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940 · see citing works

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Kelly, W. K., O’Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M. L., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Secrist, J. P., Schwartz, L. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 906 · see citing works

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687 · see citing works

Passing the baton: the HIF switch

Koh, M. Y., & Powis, G. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.06.004 · Cited by 589 · see citing works

Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma

Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448 · see citing works

Gelatinase B: a tuner and amplifier of immune functions

Opdenakker, G., den Steen, P. E. V., & Damme, J. V. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02023-3 · Cited by 398 · see citing works

Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396 · see citing works

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393 · see citing works

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A. P., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 360 · see citing works

Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation.

Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Ki, K., Hosokawa, M., & Asaka, M. (2001) · PubMed · Cited by 341 · see citing works

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336 · see citing works

Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival

Choudhry, H., Albukhari, A., Morotti, M., Haider, S. A., Moralli, D., Smythies, J., Schödel, J., Green, C., Camps, C., Buffa, F. M., et al. (2014) · Oncogene · doi:10.1038/onc.2014.378 · Cited by 317 · see citing works

Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia

Kaidi, A., Qualtrough, D., Williams, A. C., & Paraskeva, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0425 · Cited by 300 · see citing works

Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., Verbois, L., Morse, D. E., Jee, J. M., Pope, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2672 · Cited by 264 · see citing works

Intratumoral hypoxia, radiation resistance, and HIF-1

Semenza, G. L. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00118-7 · Cited by 235 · see citing works

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Krug, L. M., Kindler, H. L., Calvert, H., Manegold, C., Tsao, A. S., Fennell, D. A., Öhman, R., Plummer, R., Eberhardt, W., Fukuoka, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70056-2 · Cited by 215 · see citing works

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

Bottsford-Miller, J. N., Coleman, R. L., & Sood, A. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9242 · Cited by 199 · see citing works

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Heath, E. I., Hillman, D. W., Vaishampayan, U. N., Sheng, S., Sarkar, F. H., Harper, F. W. K., Gaskins, M., Pitot, H. C., Tan, W. W., Ivy, S. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0221 · Cited by 186 · see citing works

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179 · see citing works

Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status

Messai, Y., Gad, S., Noman, M. Z., Le Teuff, G., Couve, S., Janji, B., Kammerer, S. F., Rioux-Leclerc, N., Hasmim, M., Ferlicot, S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.029 · Cited by 168 · see citing works

Nelfinavir Down-regulates Hypoxia-Inducible Factor 1α and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy

Pore, N., Gupta, A., Cerniglia, G. J., Jiang, Z., Bernhard, E. J., Evans, S. M., Koch, C. J., Hahn, S. M., & Maity, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1239 · Cited by 157 · see citing works

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

Ronnen, E. A., Kondagunta, G. V., Ishill, N. M., Sweeney, S. M., DeLuca, J., Schwartz, L. H., Bacik, J., & Motzer, R. J. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9208-z · Cited by 147 · see citing works

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., Qian, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2948 · Cited by 142 · see citing works

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

Zhao, D., Zhai, B., He, C., Tan, G., Jiang, X. L., Pan, S., Dong, X., Wei, Z., Ma, L., Qiao, H., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.026 · Cited by 142 · see citing works

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma

Ogura, M., Ando, K., Suzuki, T., Ishizawa, K., Oh, S. Y., Itoh, K., Yamamoto, K., Au, W. Y., Tien, H., Matsuno, Y., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12819 · Cited by 111 · see citing works

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Harrison, M. R., Hahn, N. M., Пили, Р., Oh, W. K., Hammers, H. J., Sweeney, C. J., Kim, K., Perlman, S. B., Arnott, J., Sidor, C. F., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9455-x · Cited by 110 · see citing works

Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial

Matei, D. E., Schilder, J. M., Sutton, G. P., Perkins, S. M., Breen, T., Quon, C. Y., & Sidor, C. F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.042 · Cited by 101 · see citing works

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J. C., Пили, Р., Logan, T. F., Carducci, M. A., Arnott, J., Treston, A. M., Wilding, G., & Liu, G. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9618-9 · Cited by 88 · see citing works

Hypoxia‐inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression

Sowa, T., Menju, T., Chen-Yoshikawa, T. F., Takahashi, K., Nishikawa, S., Nakanishi, T., Shikuma, K., Motoyama, H., Hijiya, K., Aoyama, A., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.991 · Cited by 88 · see citing works

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

Kulke, M. H., Chan, J. A., Meyerhardt, J. A., Zhu, A. X., Abrams, T. A., Blaszkowsky, L. S., Regan, E. M., Sidor, C. F., & Fuchs, C. S. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1478-7 · Cited by 86 · see citing works

A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1α, 2α and 3α)

Luo, J. C., & Shibuya, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204228 · Cited by 80 · see citing works

Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1α/BNIP3 signaling pathway

Wu, H., Huang, S., Chen, Z., Liu, W., Zhou, X., & Zhang, D. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4255 · Cited by 79 · see citing works

HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer

Yang, J., Zhang, X., Zhang, Y., Zhu, D., Zhang, L., Li, Y., Zhu, Y., Li, D., & Zhou, J. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0298-y · Cited by 76 · see citing works

Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma

Rajkumar, S. V., Richardson, P. G. G., Lacy, M. Q., Dispenzieri, A. A., Greipp, P. R., Witzig, T. E., Schlossman, R. L., Sidor, C. F., Anderson, K. C., & Gertz, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0807 · Cited by 75 · see citing works

Phase II trial of vorinostat in advanced melanoma

Haas, N. B., Quirt, I. C., Hotte, S. J., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0066-9 · Cited by 71 · see citing works

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma

Dai, X., Pi, G., Yang, S., Chen, G. Y., Liu, L., & Dong, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.02.014 · Cited by 63 · see citing works

Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

Garrett, C. R., Bekaii‐Saab, T. S., Ryan, T., Fisher, G. A., Clive, S., Kavan, P., Shacham‐Shmueli, E., Buchbinder, A., & Goldberg, R. M. (2013) · Cancer · doi:10.1002/cncr.28358 · Cited by 62 · see citing works

Prognosis value of HIF-1α expression in patients with non-small cell lung cancer

Wang, Q., Hu, D.-F., Rui, Y., Jiang, A., Liu, Z., & Huang, L. (2014) · Gene · doi:10.1016/j.gene.2014.03.025 · Cited by 52 · see citing works

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

O’Keefe, S. J., Hoffman-Censits, J. H., Cohen, R. B., Mamtani, R., Heitjan, D. F., Eliasof, S. D., Nixon, A. B., Turnbull, B., Garmey, E. G., Gunnarsson, Ö., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw188 · Cited by 52 · see citing works

HIF-1α Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function

Yoo, Y., Christensen, J., & Huang, E. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2360 · Cited by 50 · see citing works

Overexpression of HIF-1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis

Fan, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.1746 · Cited by 49 · see citing works

HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer

Sun, Y., Guan, Z., Liang, L., Cheng, Y., Zhou, J., Li, J., & XU, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4536 · Cited by 41 · see citing works

HIF-2α not HIF-1α overexpression confers poor prognosis in non–small cell lung cancer

Gao, Z., Wang, Y., Yuan, W.-D., Yuan, J.-Q., & Yuan, K. (2017) · Tumor Biology · doi:10.1177/1010428317709637 · Cited by 37 · see citing works

HIF-1α Promotes Breast Cancer Cell MCF-7 Proliferation and Invasion Through Regulating miR-210

Zhang, Y., Yan, J., Wang, L., Dai, H., Li, N., Hu, W., & Cai, H. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2270 · Cited by 37 · see citing works

HIF-1α- and hypoxia-dependent immune responses in human CD4+CD25high T cells and T helper 17 cells

Bollinger, T., Gies, S. E., Naujoks, J., Feldhoff, L., Bollinger, A., Solbach, W., & Rupp, J. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0813-426rr · Cited by 33 · see citing works

Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis

ZHENG, Y., Ni, Y., Huang, X., Wang, Z., & Han, W. (2013) · Oncology Letters · doi:10.3892/ol.2013.1185 · Cited by 32 · see citing works

Expression of HIF-1α in medullary thyroid cancer identifies a subgroup with poor prognosis

Lodewijk, L., van Diest, P. J., van der Groep, P., ter Hoeve, N. D., Schepers, A., Morreau, J., Bonenkamp, J. J., Grunsven, A. C. H. V. E., Kruijff, S., van Hemel, B. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15622 · Cited by 30 · see citing works

SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1α

OKUNO, T., Kawai, K., Hata, K., Murono, K., Emoto, S., Kaneko, M., Sasaki, K., Nishikawa, T., Tanaka, T., & Nozawa, H. (2018) · Anticancer Research · doi:10.21873/anticanres.12598 · Cited by 30 · see citing works

HIF-1–Dependent Stromal Adaptation to Ischemia Mediates In Vivo Tumor Radiation Resistance

Schwartz, D. L., Bankson, J. A., Bidaut, L. M., He, Y., Williams, R. R., Lemos, R., Thitai, A. K., Oh, J., Volgin, A., Soghomonyan, S., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0469 · Cited by 27 · see citing works

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

Oki, Y., Copeland, A. R. M., Romaguera, J. E., Fayad, L., Fanale, M. A., Faria, S. D. C., Medeiros, L. J., Ivy, P. S., & Younes, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.631236 · Cited by 21 · see citing works

The prognosis outcome of oral squamous cell carcinoma using HIF-2α

Lim, E., Kuo, C., Tu, H., & Yang, C. (2017) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2017.06.005 · Cited by 19 · see citing works

HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma

Lai, X., Liu, S., Tsai, Y.-T., Sun, G., Chang, S., Huang, S., & Cha, T. (2017) · Oncotarget · doi:10.18632/oncotarget.17923 · Cited by 18 · see citing works

Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin

Gao, Z., Yuan, W.-D., Yuan, J.-Q., Yuan, K., & Wang, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.906107 · Cited by 12 · see citing works

Relationship between CD4+CD25+ Treg and expression of HIF-1α and Ki-67 in NSCLC patients.

He, L.-Y., Li, L., Guo, M.-L., Zhang, Y., & Hz, Z. (2015) · PubMed · Cited by 10 · see citing works

Hypoxia and the Tumor Microenvironment

Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 397 · see citing works

Hypoxia-Driven Immune Escape in the Tumor Microenvironment

Vito, A., El-Sayes, N., & Mossman, K. L. (2020) · Cells · doi:10.3390/cells9040992 · Cited by 274 · see citing works

RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential

Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., & Cai, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01224-4 · Cited by 264 · see citing works

Mitochondria Targeting as an Effective Strategy for Cancer Therapy

Ghosh, P., Vidal, C., Dey, S., & Li, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 267 · see citing works

Targeting hypoxia-inducible factors: therapeutic opportunities and challenges

Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245 · see citing works

Tumor hypoxia: From basic knowledge to therapeutic implications

Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223 · see citing works

The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment

Hayes, C., Donohoe, C. L., Davern, M., & Donlon, N. E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.021 · Cited by 215 · see citing works

Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications

Wei, Q., Qian, Y., Yu, J. Q., & Wong, C. C. (2020) · Oncogene · doi:10.1038/s41388-020-01432-7 · Cited by 188 · see citing works

Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway

Sondermann, N. C., Faßbender, S., Hartung, F., Hätälä, A. M., Rolfes, K. M., Vogel, C. F. A., & Haarmann‐Stemmann, T. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115371 · Cited by 190 · see citing works

Hypoxia-induced epithelial to mesenchymal transition in cancer

Hapke, R., & Haake, S. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.012 · Cited by 181 · see citing works

Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons

Akman, M., Belisario, D. C., Salaroglio, I. C., Kopecka, J., Donadelli, M., Smaele, E. D., & Riganti, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01824-3 · Cited by 176 · see citing works

Crosstalk between Hypoxia and ER Stress Response: a Key Regulator of Macrophage Polarization

Díaz-Bulnes, P., Saiz, M. L., López-Larrea, C., & Rodríguez, R. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02951 · Cited by 175 · see citing works

HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells

Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169 · see citing works

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162 · see citing works

The amoeboid state as part of the epithelial-to-mesenchymal transition programme

Graziani, V., Rodríguez‐Hernández, I., Maiques, Ó., & Sanz‐Moreno, V. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.10.004 · Cited by 162 · see citing works

Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

Bui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 164 · see citing works

Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing

Kabakov, A. E., & Yakimova, A. O. (2021) · Cancers · doi:10.3390/cancers13051102 · Cited by 161 · see citing works

The crosstalk between HIFs and mitochondrial dysfunctions in cancer development

Bao, X., Zhang, J., Huang, G., Yan, J., Xu, C., Dou, Z., Sun, C., & Zhang, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03505-1 · Cited by 152 · see citing works

Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications

Shi, R., Liao, C., & Zhang, Q. H. (2021) · Cells · doi:10.3390/cells10030678 · Cited by 148 · see citing works

Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 140 · see citing works

Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance

Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133 · see citing works

Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations

Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 135 · see citing works

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

Samec, M., Líšková, A., Koklesová, L., Meršaková, S., Strnádel, J., Kajo, K., Péč, M. J., Zhai, K., Šmejkal, K., Mirzaei, S., et al. (2021) · Cancers · doi:10.3390/cancers13010130 · Cited by 114 · see citing works

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy

Shurin, M. R., & Umansky, V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159473 · Cited by 113 · see citing works

Retinopathy of prematurity: A review of pathophysiology and signaling pathways

Fevereiro‐Martins, M., Marques‐Neves, C., Guimarães, H., & Bicho, M. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.11.007 · Cited by 114 · see citing works

Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies

Zhou, X., An, B., Lin, Y., Ni, Y., Zhao, X., & Liang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115036 · Cited by 107 · see citing works

The role of HIF proteins in maintaining the metabolic health of the intervertebral disc

Silagi, E. S., Schipani, E., Shapiro, I. M., & Risbud, M. V. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00621-2 · Cited by 108 · see citing works

The interplay of hypoxic and mental stress: Implications for anxiety and depressive disorders

Burtscher, J., Niedermeier, M., Hüfner, K., van den Burg, E. H., Kopp, M., Stoop, R., Burtscher, M., Gatterer, H., & Millet, G. P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104718 · Cited by 104 · see citing works

Hypoxia-mediated drug resistance in breast cancers

McAleese, C. E., Choudhury, C., Butcher, N. J., & Minchin, R. F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.045 · Cited by 99 · see citing works

Hypoxia/HIF Modulates Immune Responses

Chen, Y., & Gaber, T. (2021) · Biomedicines · doi:10.3390/biomedicines9030260 · Cited by 100 · see citing works

Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia

Toledo, R. A., Jiménez, C., Armaiz-Peña, G., Arenillas, C., Capdevila, J., & Dahia, P. L. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac025 · Cited by 98 · see citing works

HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer

Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.027 · Cited by 95 · see citing works

Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments

de la Torre, P., Pérez-Lorenzo, M. J., Alcazar-Garrido, A., & Flores, A. I. (2020) · Molecules · doi:10.3390/molecules25030715 · Cited by 95 · see citing works

Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment

Kim, I., Choi, S., Yoo, S., Lee, M., & Kim, I. (2022) · Cancers · doi:10.3390/cancers14143321 · Cited by 98 · see citing works

Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance

Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02724-y · Cited by 89 · see citing works

Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy

Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83 · see citing works

The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer

Yong, L., Tang, S., Yu, H., Zhang, H., Zhang, Y., Wan, Y., & Cai, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964934 · Cited by 78 · see citing works

HIF: a master regulator of nutrient availability and metabolic cross‐talk in the tumor microenvironment

Missiaen, R., Lesner, N. P., & Simon, M. C. (2023) · The EMBO Journal · doi:10.15252/embj.2022112067 · Cited by 74 · see citing works

WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways

Chen, T., Li, K., Liu, Z., Liu, J., Wang, Y., Sun, R., Li, Z., Qiu, B., Zhang, X., Ren, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.017 · Cited by 72 · see citing works

Re-engineering natural products to engage new biological targets

Motika, S. E., & Hergenrother, P. J. (2020) · Natural Product Reports · doi:10.1039/d0np00059k · Cited by 69 · see citing works

Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality

Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68 · see citing works

Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions

Busk, M., Overgaard, J., & Horsman, M. R. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.05.003 · Cited by 66 · see citing works

Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer

Wu, D., Dasgupta, A., Read, A. D., Bentley, R. E. T., Motamed, M., Chen, K., Al‐Qazazi, R., Mewburn, J. D., Dunham‐Snary, K. J., Alizadeh, E., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.452 · Cited by 69 · see citing works

Hypoxia pathway proteins and their impact on the blood vasculature

Rodriguez, D., Watts, D., Gaete, D., Sormendi, S., & Wielockx, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179191 · Cited by 62 · see citing works

Metabolic Reprogramming in COVID-19

Shen, T., & Wang, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111475 · Cited by 60 · see citing works

Contribution of hypoxia inducible factor-1 during viral infections

Reyes, A., Corrales, N., Gálvez, N. M. S., Bueno, S. M., Kalergis, A. M., & González, P. A. (2020) · Virulence · doi:10.1080/21505594.2020.1836904 · Cited by 58 · see citing works

Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury

Li, X., Berg, N. K., Mills, T., Zhang, K., Eltzschig, H. K., & Yuan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604944 · Cited by 59 · see citing works

Comparative Biology of Oxygen Sensing in Plants and Animals

Holdsworth, M. J., & Gibbs, D. J. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.021 · Cited by 57 · see citing works

Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis

Shi, Y., Gong, M., Deng, Z., Liu, H., Chang, Y., Yang, Z., & Cai, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.036 · Cited by 55 · see citing works

Targeting the Redox Landscape in Cancer Therapy

Narayanan, D., Ma, S., & Özcelik, D. (2020) · Cancers · doi:10.3390/cancers12071706 · Cited by 54 · see citing works

The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer

Metin, C. U., & Özcan, G. (2022) · Cancers · doi:10.3390/cancers14112711 · Cited by 53 · see citing works

P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases

Mishra, A., Behura, A., Kumar, A., Naik, L., Swain, A., Das, M., Sarangi, S. S., Dokania, P., Dirisala, V. R., Bhutia, S. K., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174235 · Cited by 53 · see citing works

Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis

Tang, X., Chang, C., Hao, M., Chen, M., Woodley, D. T., Schönthal, A. H., & Li, W. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00316-6 · Cited by 51 · see citing works

Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy

Huang, Z., Huang, S., Song, S., Ding, Y., Zhou, H., Zhang, S., Weng, L., Zhang, Y., Hu, Y., Yuan, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53084-w · Cited by 52 · see citing works

NADPH Oxidase 4 (NOX4) in Cancer: Linking Redox Signals to Oncogenic Metabolic Adaptation

Szántó, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052702 · Cited by 49 · see citing works

On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy

Dutcher, J. P., Flippot, R., Fallah, J., & Escudier, B. J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280817 · Cited by 51 · see citing works

Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer

Zhao, C., Zeng, C., Ye, S., Dai, X., He, Q., Yang, B., & Zhu, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.010 · Cited by 49 · see citing works

Hypoxia-driven epigenetic regulation in cancer progression: A focus on histone methylation and its modifying enzymes

Kim, I., & Park, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.025 · Cited by 48 · see citing works

Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer

Barth, D. A., Prinz, F., Teppan, J., Jonas, K., Klec, C., & Pichler, M. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030027 · Cited by 48 · see citing works

Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy

Hensen, L. C. M., Hoeben, R. C., & Bots, S. T. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186828 · Cited by 48 · see citing works

Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling

Yang, H., Geng, Y., Wang, P., Zhang, H., Fang, W., & Tian, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04647-6 · Cited by 48 · see citing works

Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors

Casillas, A. L., Chauhan, S. S., Toth, R. K., Sainz, A. G., Clements, A. N., Jensen, C. C., Langlais, P. R., Miranti, C. K., Cress, A. E., & Warfel, N. A. (2021) · Oncogene · doi:10.1038/s41388-021-01915-1 · Cited by 44 · see citing works

Calpain‐1 mediates vascular remodelling and fibrosis via HIF‐1α in hypoxia‐induced pulmonary hypertension

Deng, H., Tian, X., Sun, H., Liu, H., Lü, M., & Wang, H. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17295 · Cited by 44 · see citing works

Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp

Hijazi, M. A., Gessner, A., & El‐Najjar, N. (2023) · Cancers · doi:10.3390/cancers15123199 · Cited by 42 · see citing works

Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities

Borde, S., & Matosevic, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.009 · Cited by 41 · see citing works

The potential roles of HIF-1α in epithelial-mesenchymal transition and ferroptosis in tumor cells

Shen, Z., Yu, N. H., Zhang, Y., Jia, M., Sun, Y., Li, Y., & Zhao, L. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111345 · Cited by 40 · see citing works

Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)

Ban, H. S., Uto, Y., & Nakamura, H. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874345 · Cited by 40 · see citing works

Retinal Diseases Regulated by Hypoxia—Basic and Clinical Perspectives: A Comprehensive Review

Shinojima, A., Lee, D., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235496 · Cited by 42 · see citing works

Perspectives on Hypoxia Signaling in Tumor Stroma

Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39 · see citing works

The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer

Li, Y., Wang, J., Wang, H., Zhang, S., Wei, Y., & Liu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850093 · Cited by 39 · see citing works

The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis

Hudler, P., & Urbančič, M. (2022) · Genes · doi:10.3390/genes13020362 · Cited by 38 · see citing works

Expression and regulation of HIF-1a in hypoxic pulmonary hypertension: Focus on pathological mechanism and Pharmacological Treatment

Wan, J.-J., Yi, J., Wang, F.-Y., Zhang, C., & Dai, A.-G. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.88216 · Cited by 37 · see citing works

Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma

Liu, J., Chen, T., Yang, M., Zhong, Z., Ni, S., Yang, S., Shao, F., Cai, L., Bai, J., & Yu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.753004 · Cited by 36 · see citing works

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)

Song, C. W., Kim, H., Cho, H., Kim, M., Paek, S.-H., Park, H. J., Griffin, R. J., Terezakis, S. A., & Cho, L. C. (2022) · Cancers · doi:10.3390/cancers14133273 · Cited by 35 · see citing works

Hypoxia-regulated microRNAs: the molecular drivers of tumor progression

Sawai, S., Wong, P., & Ramasamy, T. S. (2022) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2022.2088684 · Cited by 35 · see citing works

The Immunotherapy Landscape in Renal Cell Carcinoma

Brown, L. C., Desai, K. B., Zhang, T., & Ornstein, M. C. (2020) · BioDrugs · doi:10.1007/s40259-020-00449-4 · Cited by 34 · see citing works

HIF-1α modulates sex-specific Th17/Treg responses during hepatic amoebiasis

Groneberg, M., Hoenow, S., Marggraff, C., Fehling, H., Metwally, N. G., Hansen, C. S., Bruchhaus, I., Tiegs, G., Sellau, J., & Lotter, H. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.020 · Cited by 36 · see citing works

Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease

Lyu, Y., Yang, X., Yang, L., Dai, J., Qin, H., Zhou, Y., Huang, Y., Wang, Y., Wu, D., Shuai, Q., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.011 · Cited by 37 · see citing works

Distinct roles for the hypoxia-inducible transcription factors HIF-1α and HIF-2α in human osteoclast formation and function

Knowles, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-78003-z · Cited by 35 · see citing works

Retinopathy of prematurity: contribution of inflammatory and genetic factors

Fevereiro‐Martins, M., Guimarães, H., Marques‐Neves, C., & Bicho, M. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04394-4 · Cited by 34 · see citing works

Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance

Shaikat, A. H., Azad, S. M. A. K., Tamim, M. A. R., Ullah, M. S., Amin, M. N., Sabbir, M. K., Tarun, M. T. I., Mostaq, M. S., Sabrin, S., Mahmud, M. Z., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.07.003 · Cited by 36 · see citing works

Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research

Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33 · see citing works

Gain of HIF1 Activity and Loss of miRNA let-7d Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis

Wyss, C. B., Duffey, N., Peyvandi, S., Barras, D., Martínez-Usatorre, A., Coquoz, O., Romero, P. J., Delorenzi, M., Lorusso, G., & Rüegg, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-19-3560 · Cited by 33 · see citing works

Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells

Han, T.-H., Park, M. K., Nakamura, H., & Ban, H. S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112500 · Cited by 34 · see citing works

Neurobiology of the carotid body

López‐Barneo, J. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-323-91534-2.00010-2 · Cited by 33 · see citing works

Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing

Rajasegaran, T., How, C. W., Saud, A., Ali, A., & Lim, J. C. W. (2023) · Pharmaceuticals · doi:10.3390/ph16030451 · Cited by 33 · see citing works

Hypoxia‐Inducible Factor 1 Alpha–Mediated RelB/APOBEC3B Down‐regulation Allows Hepatitis B Virus Persistence

Riedl, T., Faure‐Dupuy, S., Rolland, M., Schuehle, S., Hizir, Z., Calderazzo, S., Zhuang, X. A., Wettengel, J. M., Lopez, M., Barnault, R., et al. (2021) · Hepatology · doi:10.1002/hep.31902 · Cited by 32 · see citing works

HIF-Dependent Mechanisms of Relationship between Hypoxia Tolerance and Tumor Development

Dzhalilova, D. S., & Makarova, O. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921100011 · Cited by 33 · see citing works

Role of dietary iron revisited: in metabolism, ferroptosis and pathophysiology of cancer.

Pandrangi, S. L., Chittineedi, P., Chikati, R., Lingareddy, J. R., Nagoor, M., & Ponnada, S. K. (2022) · PubMed Central · Cited by 32 · see citing works

Angiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy

Yan, T., & Shi, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509195 · Cited by 33 · see citing works

Sesquiterpenes and Sesquiterpene Derivatives from Ferula: Their Chemical Structures, Biosynthetic Pathways, and Biological Properties

Wang, J., Zheng, Q., Wang, H., Shi, L.-L., Wang, G., Zhao, Y., Fan, C., & Si, J. (2023) · Antioxidants · doi:10.3390/antiox13010007 · Cited by 30 · see citing works

Review of potential medical treatments for middle ear cholesteatoma

Schürmann, M., Goon, P. K. C., & Sudhoff, H. H. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00953-w · Cited by 30 · see citing works

Hypoxia-Inducible Factors Regulate Osteoclasts in Health and Disease

Meng, X., Wielockx, B., Rauner, M., & Bözec, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.658893 · Cited by 28 · see citing works

Nuclear hormone receptor NHR-49 acts in parallel with HIF-1 to promote hypoxia adaptation in Caenorhabditis elegans

Doering, K. R. S., Cheng, X., Milburn, L. J., Ratnappan, R., Ghazi, A., Miller, D. L., & Taubert, S. (2022) · eLife · doi:10.7554/elife.67911 · Cited by 33 · see citing works

Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications

Jeon, S., Jeon, M., Choi, S., Yoo, S., Park, S.-H., Lee, M., & Kim, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054430 · Cited by 27 · see citing works

Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression

Wang, Z., Zhao, Y., An, Z., & Li, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01491 · Cited by 26 · see citing works

Molecular Insights into the Oxygen-Sensing Pathway and Erythropoietin Expression Regulation in Erythropoiesis

Tomc, J., & Debeljak, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137074 · Cited by 27 · see citing works

Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia‐inducible factor‐1α in colorectal cancer

Fang, C., Dai, L., Wang, C., Fan, C., Yu, Y., Yang, L., Deng, H., & Zhou, Z. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13044 · Cited by 27 · see citing works

Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy

Zhang, X., He, C., & Xiang, G. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.012 · Cited by 28 · see citing works

Harnessing Natural Killer Cells for Lung Cancer Therapy

Ma, S., Caligiuri, M. A., & Yu, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1097 · Cited by 27 · see citing works

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514 · see citing works

Hypoxia-inducible factors: arbitrators of cancer progression, inhibitors, and therapy

Dutta, P., Sheikh, A. A., Dan, S., & Upadhyay, S. K. (2024) · De Gruyter eBooks · doi:10.1515/9783111349541-008

Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics

Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140 · see citing works

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Yu, T., Tang, B., & Sun, X. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.489 · Cited by 192 · see citing works

Targeting the hypoxia-inducible factor (HIF) pathway in cancer

Poon, E., Harris, A. L., & Ashcroft, M. A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001173 · Cited by 210 · see citing works